Go Pro
→ Your book attached (From Profits Run) (Ad)tc pixel Free AAPG Stock Alerts

Ascentage Pharma Group International (AAPG) Competitors

Ascentage Pharma Group International logo
$16.41 +0.31 (+1.93%)
Closing price 09/14/2026 03:59 PM Eastern
Extended Trading
$16.42 +0.01 (+0.04%)
As of 09/14/2026 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

AAPG vs. KNSA, DNTH, COGT, XENE, and LGND

Should you buy Ascentage Pharma Group International stock or one of its competitors? Ascentage Pharma Group International's main competitors and comparable companies include Kiniksa Pharmaceuticals International (KNSA), Dianthus Therapeutics (DNTH), Cogent Biosciences (COGT), Xenon Pharmaceuticals (XENE), and Ligand Pharmaceuticals (LGND). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Ascentage Pharma Group International compare to Kiniksa Pharmaceuticals International?

Ascentage Pharma Group International (NASDAQ:AAPG) and Kiniksa Pharmaceuticals International (NASDAQ:KNSA) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, dividends, analyst recommendations, risk, profitability, media sentiment and institutional ownership.

Kiniksa Pharmaceuticals International has a net margin of 9.59% compared to Ascentage Pharma Group International's net margin of 0.00%. Kiniksa Pharmaceuticals International's return on equity of 13.65% beat Ascentage Pharma Group International's return on equity.

Company Net Margins Return on Equity Return on Assets
Ascentage Pharma Group InternationalN/A N/A N/A
Kiniksa Pharmaceuticals International 9.59%13.65%10.09%

Kiniksa Pharmaceuticals International has higher revenue and earnings than Ascentage Pharma Group International.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ascentage Pharma Group International$642.64M2.39-$177.71MN/AN/A
Kiniksa Pharmaceuticals International$840.85M7.11$59.01M$0.9778.95

Ascentage Pharma Group International has a beta of 0.08, meaning that its share price is 92% less volatile than the broader market. Comparatively, Kiniksa Pharmaceuticals International has a beta of 0.09, meaning that its share price is 91% less volatile than the broader market.

Ascentage Pharma Group International currently has a consensus target price of $46.43, indicating a potential upside of 182.93%. Kiniksa Pharmaceuticals International has a consensus target price of $87.38, indicating a potential upside of 14.10%. Given Ascentage Pharma Group International's stronger consensus rating and higher probable upside, research analysts plainly believe Ascentage Pharma Group International is more favorable than Kiniksa Pharmaceuticals International.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ascentage Pharma Group International
0 Sell rating(s)
0 Hold rating(s)
8 Buy rating(s)
2 Strong Buy rating(s)
3.20
Kiniksa Pharmaceuticals International
0 Sell rating(s)
2 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.80

In the previous week, Kiniksa Pharmaceuticals International had 1 more articles in the media than Ascentage Pharma Group International. MarketBeat recorded 3 mentions for Kiniksa Pharmaceuticals International and 2 mentions for Ascentage Pharma Group International. Kiniksa Pharmaceuticals International's average media sentiment score of 1.35 beat Ascentage Pharma Group International's score of 0.45 indicating that Kiniksa Pharmaceuticals International is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Ascentage Pharma Group International
0 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Kiniksa Pharmaceuticals International
1 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

54.0% of Kiniksa Pharmaceuticals International shares are owned by institutional investors. 52.0% of Kiniksa Pharmaceuticals International shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Kiniksa Pharmaceuticals International beats Ascentage Pharma Group International on 11 of the 14 factors compared between the two stocks.

How does Ascentage Pharma Group International compare to Dianthus Therapeutics?

Ascentage Pharma Group International (NASDAQ:AAPG) and Dianthus Therapeutics (NASDAQ:DNTH) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, dividends, earnings, media sentiment, risk and profitability.

Dianthus Therapeutics has lower revenue, but higher earnings than Ascentage Pharma Group International.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ascentage Pharma Group International$642.64M2.39-$177.71MN/AN/A
Dianthus Therapeutics$2.04M2,885.99-$162.34M-$4.15N/A

Ascentage Pharma Group International presently has a consensus target price of $46.43, suggesting a potential upside of 182.93%. Dianthus Therapeutics has a consensus target price of $129.83, suggesting a potential upside of 20.56%. Given Ascentage Pharma Group International's stronger consensus rating and higher probable upside, analysts plainly believe Ascentage Pharma Group International is more favorable than Dianthus Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ascentage Pharma Group International
0 Sell rating(s)
0 Hold rating(s)
8 Buy rating(s)
2 Strong Buy rating(s)
3.20
Dianthus Therapeutics
1 Sell rating(s)
0 Hold rating(s)
13 Buy rating(s)
1 Strong Buy rating(s)
2.93

In the previous week, Dianthus Therapeutics had 6 more articles in the media than Ascentage Pharma Group International. MarketBeat recorded 8 mentions for Dianthus Therapeutics and 2 mentions for Ascentage Pharma Group International. Dianthus Therapeutics' average media sentiment score of 0.98 beat Ascentage Pharma Group International's score of 0.45 indicating that Dianthus Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Ascentage Pharma Group International
0 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Dianthus Therapeutics
3 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Ascentage Pharma Group International has a beta of 0.08, indicating that its share price is 92% less volatile than the broader market. Comparatively, Dianthus Therapeutics has a beta of 1.24, indicating that its share price is 24% more volatile than the broader market.

47.5% of Dianthus Therapeutics shares are held by institutional investors. 3.0% of Dianthus Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Ascentage Pharma Group International has a net margin of 0.00% compared to Dianthus Therapeutics' net margin of -10,096.95%. Ascentage Pharma Group International's return on equity of 0.00% beat Dianthus Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Ascentage Pharma Group InternationalN/A N/A N/A
Dianthus Therapeutics -10,096.95%-22.53%-21.55%

Summary

Dianthus Therapeutics beats Ascentage Pharma Group International on 8 of the 15 factors compared between the two stocks.

How does Ascentage Pharma Group International compare to Cogent Biosciences?

Ascentage Pharma Group International (NASDAQ:AAPG) and Cogent Biosciences (NASDAQ:COGT) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, media sentiment, institutional ownership, earnings, profitability and dividends.

Ascentage Pharma Group International's return on equity of 0.00% beat Cogent Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Ascentage Pharma Group InternationalN/A N/A N/A
Cogent Biosciences N/A -84.47%-47.72%

Ascentage Pharma Group International presently has a consensus price target of $46.43, suggesting a potential upside of 182.93%. Cogent Biosciences has a consensus price target of $51.56, suggesting a potential upside of 54.31%. Given Ascentage Pharma Group International's stronger consensus rating and higher probable upside, research analysts plainly believe Ascentage Pharma Group International is more favorable than Cogent Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ascentage Pharma Group International
0 Sell rating(s)
0 Hold rating(s)
8 Buy rating(s)
2 Strong Buy rating(s)
3.20
Cogent Biosciences
1 Sell rating(s)
2 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
2.75

Ascentage Pharma Group International has a beta of 0.08, suggesting that its stock price is 92% less volatile than the broader market. Comparatively, Cogent Biosciences has a beta of 0.31, suggesting that its stock price is 69% less volatile than the broader market.

Ascentage Pharma Group International has higher revenue and earnings than Cogent Biosciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ascentage Pharma Group International$642.64M2.39-$177.71MN/AN/A
Cogent BiosciencesN/AN/A-$328.94M-$2.16N/A

In the previous week, Cogent Biosciences had 1 more articles in the media than Ascentage Pharma Group International. MarketBeat recorded 3 mentions for Cogent Biosciences and 2 mentions for Ascentage Pharma Group International. Cogent Biosciences' average media sentiment score of 1.24 beat Ascentage Pharma Group International's score of 0.45 indicating that Cogent Biosciences is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Ascentage Pharma Group International
0 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Cogent Biosciences
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Ascentage Pharma Group International beats Cogent Biosciences on 7 of the 10 factors compared between the two stocks.

How does Ascentage Pharma Group International compare to Xenon Pharmaceuticals?

Xenon Pharmaceuticals (NASDAQ:XENE) and Ascentage Pharma Group International (NASDAQ:AAPG) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, institutional ownership, media sentiment, risk, dividends, analyst recommendations, profitability and earnings.

In the previous week, Xenon Pharmaceuticals had 5 more articles in the media than Ascentage Pharma Group International. MarketBeat recorded 7 mentions for Xenon Pharmaceuticals and 2 mentions for Ascentage Pharma Group International. Xenon Pharmaceuticals' average media sentiment score of 0.82 beat Ascentage Pharma Group International's score of 0.45 indicating that Xenon Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Xenon Pharmaceuticals
3 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Positive
Ascentage Pharma Group International
0 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Xenon Pharmaceuticals has a beta of 0.61, meaning that its stock price is 39% less volatile than the broader market. Comparatively, Ascentage Pharma Group International has a beta of 0.08, meaning that its stock price is 92% less volatile than the broader market.

Xenon Pharmaceuticals presently has a consensus target price of $77.13, suggesting a potential upside of 32.55%. Ascentage Pharma Group International has a consensus target price of $46.43, suggesting a potential upside of 182.93%. Given Ascentage Pharma Group International's stronger consensus rating and higher possible upside, analysts plainly believe Ascentage Pharma Group International is more favorable than Xenon Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Xenon Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
14 Buy rating(s)
2 Strong Buy rating(s)
3.00
Ascentage Pharma Group International
0 Sell rating(s)
0 Hold rating(s)
8 Buy rating(s)
2 Strong Buy rating(s)
3.20

Ascentage Pharma Group International has higher revenue and earnings than Xenon Pharmaceuticals.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Xenon Pharmaceuticals$7.50M750.03-$345.91M-$4.74N/A
Ascentage Pharma Group International$642.64M2.39-$177.71MN/AN/A

Ascentage Pharma Group International's return on equity of 0.00% beat Xenon Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Xenon PharmaceuticalsN/A -43.98% -41.72%
Ascentage Pharma Group International N/A N/A N/A

95.5% of Xenon Pharmaceuticals shares are held by institutional investors. 2.9% of Xenon Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Xenon Pharmaceuticals beats Ascentage Pharma Group International on 7 of the 13 factors compared between the two stocks.

How does Ascentage Pharma Group International compare to Ligand Pharmaceuticals?

Ligand Pharmaceuticals (NASDAQ:LGND) and Ascentage Pharma Group International (NASDAQ:AAPG) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, dividends, media sentiment, institutional ownership and risk.

Ligand Pharmaceuticals currently has a consensus target price of $335.75, suggesting a potential upside of 19.63%. Ascentage Pharma Group International has a consensus target price of $46.43, suggesting a potential upside of 182.93%. Given Ascentage Pharma Group International's stronger consensus rating and higher probable upside, analysts clearly believe Ascentage Pharma Group International is more favorable than Ligand Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ligand Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
3.00
Ascentage Pharma Group International
0 Sell rating(s)
0 Hold rating(s)
8 Buy rating(s)
2 Strong Buy rating(s)
3.20

Ligand Pharmaceuticals has a net margin of 67.88% compared to Ascentage Pharma Group International's net margin of 0.00%. Ligand Pharmaceuticals' return on equity of 20.06% beat Ascentage Pharma Group International's return on equity.

Company Net Margins Return on Equity Return on Assets
Ligand Pharmaceuticals67.88% 20.06% 11.68%
Ascentage Pharma Group International N/A N/A N/A

91.3% of Ligand Pharmaceuticals shares are owned by institutional investors. 5.6% of Ligand Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Ligand Pharmaceuticals has higher earnings, but lower revenue than Ascentage Pharma Group International.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ligand Pharmaceuticals$268.09M20.87$124.45M$9.3530.02
Ascentage Pharma Group International$642.64M2.39-$177.71MN/AN/A

Ligand Pharmaceuticals has a beta of 1.11, suggesting that its stock price is 11% more volatile than the broader market. Comparatively, Ascentage Pharma Group International has a beta of 0.08, suggesting that its stock price is 92% less volatile than the broader market.

In the previous week, Ligand Pharmaceuticals had 8 more articles in the media than Ascentage Pharma Group International. MarketBeat recorded 10 mentions for Ligand Pharmaceuticals and 2 mentions for Ascentage Pharma Group International. Ligand Pharmaceuticals' average media sentiment score of 1.10 beat Ascentage Pharma Group International's score of 0.45 indicating that Ligand Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Ligand Pharmaceuticals
7 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Ascentage Pharma Group International
0 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Ligand Pharmaceuticals beats Ascentage Pharma Group International on 11 of the 15 factors compared between the two stocks.

Get Ascentage Pharma Group International News Delivered to You Automatically

Sign up to receive the latest news and ratings for AAPG and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AAPG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AAPG vs. The Competition

Export
MetricAscentage Pharma Group InternationalBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$1.50B$3.86B$7.15B$13.98B
Dividend YieldN/A3.66%2.57%11.71%
P/E RatioN/A14.33273.2825.37
Price / Sales2.391,345.75615.1775.12
Price / CashN/A43.6428.4234.96
Price / Book8.0415.2610.436.24
Net Income-$177.71M-$22.78M$3.49B$358.08M
7 Day Performance-5.91%-0.79%-1.15%-0.70%
1 Month Performance-12.92%2.12%0.56%-2.76%
1 Year Performance-57.52%41.90%20.17%6.72%

Ascentage Pharma Group International Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AAPG
Ascentage Pharma Group International
3.0747 of 5 stars		$16.41
+1.9%		$46.43
+182.9%		-59.4%$1.50B$642.64MN/A767
KNSA
Kiniksa Pharmaceuticals International
4.2145 of 5 stars		$76.94
+0.6%		$87.38
+13.6%		+106.4%$6.00B$677.56M79.31366
DNTH
Dianthus Therapeutics
2.1856 of 5 stars		$107.34
+3.9%		$129.83
+21.0%		+189.8%$5.88B$2.04MN/A92
COGT
Cogent Biosciences
1.9795 of 5 stars		$33.53
-1.6%		$51.56
+53.8%		+163.9%$5.82BN/AN/A258
XENE
Xenon Pharmaceuticals
2.2907 of 5 stars		$58.96
+0.3%		$77.13
+30.8%		+60.7%$5.70B$7.50MN/A370

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:AAPG) was last updated on 9/15/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
They didn't warn anyone in 1971. This time someone is warning you.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
These gold assets are priced for $1,800 gold [it's over $4,000]
Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...
Golden Portfolio | Sponsoredtc pixel